We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+35.2%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.01B
AUM Growth
+$314M
Cap. Flow
+$143M
Cap. Flow %
14.12%
Top 10 Hldgs %
64.85%
Holding
53
New
6
Increased
8
Reduced
14
Closed
16

Top Buys

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$111M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$50M
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$19.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$18.9M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$17.8M

Top Sells

Rank Stock Value
1
COLL icon
Collegium Pharmaceutical
COLL
+$14.7M
2
BLUE
bluebird bio
BLUE
+$14.3M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$12.6M
4
ARDX icon
Ardelyx
ARDX
+$9.17M
5
TXMD icon
TherapeuticsMD
TXMD
+$8.9M

Sector Composition

Rank Sector Weight
1 Healthcare 84.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGRX
51
DELISTED
Agile Therapeutics
AGRX
– –
-315
Closed -$4.25M
EPZM
52
DELISTED
Epizyme, Inc
EPZM
– –
-227,092
Closed -$2.92M
WGBS
53
DELISTED
WaferGen Bio-systems, Inc.
WGBS
– –
-41,080
Closed -$279K
1 2
3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, RA Capital Management held 53 positions worth $1.01B, up 45% from $696M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

RA Capital Management deployed $143M of net new capital in Q4 2015, opening 6 new positions and adding to 8 existing holdings. Its largest new stake was Wave Life Sciences: 7,088,651 shares worth $113M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier.

On the sell side, the largest reduction was Collegium Pharmaceutical, an estimated $14.7M trimmed.

  • RA Capital Management's largest Q4 2015 buy was Wave Life Sciences: 7,088,651 shares worth $113M.
  • RA Capital Management added most to BioCryst Pharmaceuticals in Q4 2015, an estimated $18.9M increase.
  • RA Capital Management's biggest Q4 2015 reduction was Collegium Pharmaceutical, cutting an estimated $14.7M.
  • RA Capital Management fully exited bluebird bio in Q4 2015, selling an estimated $14.3M.
  • RA Capital Management's ten largest holdings make up 65% of its $1.01B portfolio in Q4 2015.
  • RA Capital Management opened 6 new positions and closed 16 in Q4 2015.
  • RA Capital Management's portfolio value rose 45% quarter-over-quarter to $1.01B.

Based on RA Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.